Department of Surgery, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, People's Republic of China.
Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, 2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Int J Nanomedicine. 2024 Jul 3;19:6693-6715. doi: 10.2147/IJN.S466490. eCollection 2024.
Colorectal cancer (CRC) is a common type of gastrointestinal tract (GIT) cancer and poses an enormous threat to human health. Current strategies for metastatic colorectal cancer (mCRC) therapy primarily focus on chemotherapy, targeted therapy, immunotherapy, and radiotherapy; however, their adverse reactions and drug resistance limit their clinical application. Advances in nanotechnology have rendered lipid nanoparticles (LNPs) a promising nanomaterial-based drug delivery system for CRC therapy. LNPs can adapt to the biological characteristics of CRC by modifying their formulation, enabling the selective delivery of drugs to cancer tissues. They overcome the limitations of traditional therapies, such as poor water solubility, nonspecific biodistribution, and limited bioavailability. Herein, we review the composition and targeting strategies of LNPs for CRC therapy. Subsequently, the applications of these nanoparticles in CRC treatment including drug delivery, thermal therapy, and nucleic acid-based gene therapy are summarized with examples provided. The last section provides a glimpse into the advantages, current limitations, and prospects of LNPs in the treatment of CRC.
结直肠癌(CRC)是一种常见的胃肠道(GIT)癌症,对人类健康构成巨大威胁。目前转移性结直肠癌(mCRC)治疗的策略主要集中在化疗、靶向治疗、免疫治疗和放疗上;然而,它们的不良反应和耐药性限制了它们的临床应用。纳米技术的进步使脂质纳米粒(LNPs)成为一种很有前途的基于纳米材料的 CRC 治疗药物输送系统。LNPs 通过改变其配方来适应 CRC 的生物学特性,使药物能够选择性地输送到癌症组织。它们克服了传统疗法的局限性,如水溶性差、非特异性生物分布和有限的生物利用度。在此,我们综述了 LNPs 用于 CRC 治疗的组成和靶向策略。随后,我们通过实例总结了这些纳米粒子在 CRC 治疗中的应用,包括药物输送、热疗和基于核酸的基因治疗。最后一部分介绍了 LNPs 在 CRC 治疗中的优势、当前的局限性和前景。
Int J Nanomedicine. 2024
Semin Cancer Biol. 2021-2
Assay Drug Dev Technol. 2024
Int J Mol Sci. 2021-11-17
Acta Biomater. 2021-6
Nanomedicine (Lond). 2016-9
Pharmaceuticals (Basel). 2025-2-14
Int J Nanomedicine. 2024-12-27
Bioact Mater. 2024-3-16
Nat Rev Drug Discov. 2024-4
Curr Opin Biotechnol. 2024-2